These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 15627288)

  • 21. New approaches to the use of antibodies for immunosuppression.
    Russell PS
    Transplant Proc; 1982 Sep; 14(3):506-8. PubMed ID: 6758236
    [No Abstract]   [Full Text] [Related]  

  • 22. Combined pancreas-kidney transplants using quadruple immunosuppression therapy: a comparison between antilymphoblast and antithymocyte globulins.
    Fasola CG; Hricik DE; Schulak JA
    Transplant Proc; 1995 Dec; 27(6):3135-6. PubMed ID: 8539880
    [No Abstract]   [Full Text] [Related]  

  • 23. Selective elimination of alpha/beta T cells as a model for peripheral T-cell tolerance.
    Dufter C; Terness P; Post S; Thies J; Otto G; Opelz G
    Transplant Proc; 1994 Dec; 26(6):3233-4. PubMed ID: 7998127
    [No Abstract]   [Full Text] [Related]  

  • 24. [Immunologic aspects of cellular therapy].
    Sukhikh GT; Bogdanova IM; Malaĭtsev VV
    Biull Eksp Biol Med; 1998 Feb; 125(2):124-9. PubMed ID: 9559117
    [No Abstract]   [Full Text] [Related]  

  • 25. Review and preview of anti-T-cell antibodies.
    Helderman JH
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):8-9. PubMed ID: 7482824
    [No Abstract]   [Full Text] [Related]  

  • 26. A myeloid-derived suppressor cell-mediated T-cell suppression assay for functional evaluation of immune cells in tumor-bearing mice.
    Bayne LJ; Vonderheide RH
    Cold Spring Harb Protoc; 2013 Sep; 2013(9):849-53. PubMed ID: 24003206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-cell-specific immunosuppression results in more than 53 days survival of porcine islets of langerhans in the monkey.
    Rijkelijkhuizen JK; Haanstra KG; Wubben J; Töns A; Roos A; van Gijlswijk-Janssen DJ; Ringers J; Bouwman E; Jonker M
    Transplantation; 2003 Nov; 76(9):1359-68. PubMed ID: 14627916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and future application of monoclonal antibodies in clinical immunosuppressive protocols.
    Cosimi AB
    Clin Transplant; 1995 Jun; 9(3 Pt 2):219-26. PubMed ID: 7670167
    [No Abstract]   [Full Text] [Related]  

  • 29. A novel therapeutic approach to 6-OHDA-induced Parkinson's disease in rats via supplementation of PTD-conjugated tyrosine hydroxylase.
    Wu SP; Fu AL; Wang YX; Yu LP; Jia PY; Li Q; Jin GZ; Sun MJ
    Biochem Biophys Res Commun; 2006 Jul; 346(1):1-6. PubMed ID: 16762325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RATG: 10 year experience in cardiac transplantation.
    Copeland JG
    Nihon Kyobu Geka Gakkai Zasshi; 1989 Sep; 37 Suppl():61. PubMed ID: 2584795
    [No Abstract]   [Full Text] [Related]  

  • 31. Selective immunosuppression with anti-T cell monoclonal antibodies.
    Chatenoud L; Bach JF
    Clin Nephrol; 1992; 38 Suppl 1():S53-60. PubMed ID: 1295709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrathymic tolerance induction is based on suppressor cells.
    Kampinga J; Klatter F; Bartels H; Pater J; Nieuwenhuis P; Roser B; Groen H
    Transplant Proc; 1994 Apr; 26(2):725-6. PubMed ID: 8171626
    [No Abstract]   [Full Text] [Related]  

  • 33. Alpha/beta, gamma/delta T cells and interleukin-2 receptor chain expression in kidney graft recipients under triple-drug immunosuppression.
    Zezina L; Kirman I; Rosental R
    Transplant Proc; 1994 Oct; 26(5):2868. PubMed ID: 7940905
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunosuppression by Fc region-mismatched anti-T cell antibody treatment.
    Thierfelder S; Mocikat R; Mysliwietz J; Lindhofer H; Kremmer E
    Eur J Immunol; 1995 Aug; 25(8):2242-6. PubMed ID: 7664787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of human chimerism and functional suppressor cells in fetal pigs: feasibility of surrogate tolerogenesis for xenotransplantation.
    Beschorner WE; Qian Z; Mattei P; Hess AD; Colombani PM; Sciscione AC; Khouzami A; Blakemore KJ; Burdick JF
    Transplant Proc; 1996 Apr; 28(2):648-9. PubMed ID: 8623323
    [No Abstract]   [Full Text] [Related]  

  • 36. Recruitment of effector T lymphocytes by initiator T lymphocytes: application for specific immunosuppression.
    Cohen IR; Belldegrün A; Ben-Nun A; Hazan R
    Transplant Proc; 1981 Mar; 13(1 Pt 1):623-5. PubMed ID: 7022903
    [No Abstract]   [Full Text] [Related]  

  • 37. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
    Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
    [No Abstract]   [Full Text] [Related]  

  • 38. Prophylaxis of graft-vs-host disease by adoptive transfer of a class II antigen-specific murine T-cell clone.
    Shih CC; Truitt RL
    Prog Clin Biol Res; 1987; 244():439-47. PubMed ID: 3116558
    [No Abstract]   [Full Text] [Related]  

  • 39. Developments in immunosuppressive therapy.
    Daar AS
    Transplant Proc; 1995 Oct; 27(5):2671-5. PubMed ID: 7482871
    [No Abstract]   [Full Text] [Related]  

  • 40. A plan to suppress or prevent the immune rejection of allografted organs.
    Jacoby M; Brock M
    Lymphology; 1992 Mar; 25(1):42-6; discussion 46-7. PubMed ID: 1533258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.